Lp(a): When to Order This Test

What Lp(a) Actually Is

Lipoprotein(a) is a low-density lipoprotein particle with an extra protein called apolipoprotein(a) bound to its surface. This protein shares structural similarity with plasminogen, the body's natural clot-dissolver, which means Lp(a) can both accelerate plaque formation and interfere with clot breakdown at the same time [1]. The LPA gene on chromosome 6 controls how much Lp(a) your liver produces, and twin studies show heritability exceeding 90% [2].

Because Lp(a) is not included in a standard lipid panel, millions of people walk around with dangerously high levels and never know it. An LDL-cholesterol of 95 mg/dL can look reassuring on paper while an unmeasured Lp(a) of 200 nmol/L quietly doubles that patient's coronary risk. A single blood draw changes that picture completely.

Lp(a) concentrations remain stable across a person's adult life. Unlike LDL-C or triglycerides, they do not swing with dietary changes, weight fluctuations, or most medications. Statins may even raise Lp(a) by 10 to 20%, though the net cardiovascular benefit of statins still outweighs this effect [3]. This stability is precisely why one-time testing works.

Who Should Be Tested and When

Every adult should have Lp(a) measured at least once. The 2024 European Atherosclerosis Society (EAS) consensus statement recommends universal measurement to identify the estimated 1.4 billion people worldwide who carry levels above 125 nmol/L [4]. The 2018 AHA/ACC cholesterol guideline lists elevated Lp(a) (≥50 mg/dL or ≥125 nmol/L) as a "risk-enhancing factor" that can tip borderline-risk patients toward statin initiation [5].

Certain populations deserve priority testing. Patients with premature atherosclerotic cardiovascular disease (ASCVD before age 55 in men or 65 in women), those with a strong family history of early heart disease, patients with familial hypercholesterolemia, and individuals whose LDL-C does not drop as expected on statin therapy should all be tested promptly [5]. The AACE 2020 consensus also flags recurrent cardiovascular events despite optimal LDL-C management as a reason to check Lp(a) [6].

Timing is straightforward. Order the test during any routine blood draw. Fasting is not required, and the result holds for life barring rare conditions like nephrotic syndrome or hypothyroidism that can transiently alter levels.

Normal Lp(a) Ranges and How to Interpret Results

The clinical cutoff for elevated Lp(a) is 50 mg/dL when reported in mass units or 125 nmol/L in molar units. These two numbers are not perfectly interchangeable because Lp(a) particle size varies between individuals, making nmol/L the more precise unit [7]. Some reference labs, including the Mayo Clinic, report in both units.

Below 30 mg/dL (75 nmol/L) is considered desirable. Between 30 and 50 mg/dL (75 to 125 nmol/L) represents borderline elevation that warrants aggressive management of all other modifiable risk factors. Above 50 mg/dL (125 nmol/L) is elevated, and above 180 nmol/L carries particularly high risk.

The risk relationship is continuous and roughly log-linear. A 2022 meta-analysis published in JAMA Cardiology pooling data from over 460,000 participants found that each 50-nmol/L increase in Lp(a) was associated with an 11% increase in major adverse cardiovascular events (HR 1.11 to 95% CI 1.09 to 1.13) [8]. Risk does not plateau at higher levels. It keeps climbing.

One measurement pitfall to watch for: some older immunoassays cross-react with plasminogen or vary by apo(a) isoform size. Isoform-insensitive immunoturbidimetric assays aligned to the WHO/IFCC reference material are preferred [4]. Ask your lab which assay they use if results seem inconsistent with clinical presentation.

What Elevated Lp(a) Means for Cardiovascular Risk

High Lp(a) is an independent, causal risk factor for coronary artery disease, ischemic stroke, peripheral artery disease, heart failure, and calcific aortic valve stenosis [1]. "Independent" means the risk persists after adjusting for LDL-C, HDL-C, triglycerides, blood pressure, diabetes, smoking, and every other known variable.

The Copenhagen General Population Study followed 69,764 individuals for a median of 7.4 years and found that participants with Lp(a) above the 95th percentile (approximately 180 nmol/L) had a 2- to 3-fold increased risk of myocardial infarction compared to those below the 22nd percentile [9]. Dr. Borge Nordestgaard, lead investigator, has stated: "Lp(a) is the strongest single genetic risk factor for cardiovascular disease that we can measure today" [10].

Aortic stenosis deserves special attention. A Mendelian randomization study in the New England Journal of Medicine demonstrated that genetically elevated Lp(a) raised the odds of aortic valve calcification and clinical aortic stenosis in a dose-dependent manner (OR 1.68 per doubling of Lp(a) concentration) [11]. No other standard lab marker predicts aortic valve disease with this specificity.

For patients with established ASCVD, elevated Lp(a) identifies residual risk that persists on optimal statin and ezetimibe therapy. The FOURIER trial substudy (N=25,096) showed that among patients already on high-intensity statins, those with Lp(a) ≥120 nmol/L had a 23% higher rate of coronary events, and evolocumab reduced Lp(a) by a median of 26.9%, which accounted for part of its benefit [12].

What a Low Lp(a) Level Means

A low Lp(a) is good news. There is no established clinical downside to having very low or undetectable Lp(a). Populations in which low Lp(a) is common, such as certain East Asian cohorts where median levels run below 20 nmol/L, show lower rates of coronary disease at any given LDL-C level [4].

Low Lp(a) does not mean zero cardiovascular risk. All other lipid parameters, blood pressure, glycemic status, and lifestyle factors still matter.

How to Lower Lp(a)

No FDA-approved medication specifically targets Lp(a) as of May 2026. Diet, exercise, and weight loss do not meaningfully change Lp(a) concentrations [2]. This is one of the most important points to communicate to patients: the number will not budge with lifestyle interventions, and that is not a personal failure.

Current management revolves around reducing total cardiovascular risk by optimizing every modifiable factor. The European Atherosclerosis Society recommends treating elevated Lp(a) as a risk enhancer that shifts treatment targets downward for LDL-C. A patient with Lp(a) of 160 nmol/L and borderline LDL-C should be treated more aggressively with statins, ezetimibe, or PCSK9 inhibitors than their LDL-C alone would dictate [4].

PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by approximately 20 to 30%, though they are not FDA-approved for this indication specifically [12]. Niacin reduces Lp(a) by 20 to 25% at high doses (2,000 to 3 to 000 mg/day), but the AIM-HIGH (N=3,414) and HPS2-THRIVE trials failed to show cardiovascular benefit from adding niacin to statin therapy, and side effects limit tolerability [13][14].

The Pipeline: RNA-Targeted Therapies

Three Lp(a)-specific therapies are in advanced clinical trials:

Pelacarsen (Novartis) is an antisense oligonucleotide that degrades LPA mRNA in the liver. The phase 2 trial showed 80% Lp(a) reduction at the 60 mg monthly dose (N=286) [15]. The phase 3 Lp(a)HORIZON trial (N=8,323) completed enrollment and results are expected in 2026.

Olpasiran (Amgen) is a small interfering RNA (siRNA) that cuts Lp(a) production by up to 101% at higher doses. The OCEAN(a)-DOSE phase 2 trial (N=281) demonstrated reductions of 70 to 101% depending on dose and interval, sustained over 36 weeks with quarterly dosing [16]. The phase 3 OCEAN(a)-Outcomes trial is underway.

Lepodisiran (Eli Lilly) is another siRNA with a single-dose phase 1 study showing near-complete Lp(a) suppression lasting beyond 48 weeks at the highest dose tested [17].

These drugs represent the first real opportunity to test the "Lp(a) hypothesis": whether directly lowering Lp(a) reduces heart attacks, strokes, and aortic valve events. The outcomes trials will define whether Lp(a)-lowering becomes standard of care.

Lp(a) and Specific Patient Populations

Familial Hypercholesterolemia

Patients with FH carry elevated Lp(a) at rates roughly double the general population. A study published in Atherosclerosis found that 30 to 50% of FH patients have Lp(a) above 50 mg/dL, compared to approximately 20% of non-FH individuals [18]. The combination of high LDL-C from defective LDL receptors and high Lp(a) from the LPA gene creates compounded risk that makes early and aggressive lipid-lowering therapy especially important.

Women and Lp(a)

Lp(a) levels tend to increase after menopause by 20 to 25%, likely due to declining estrogen, which normally suppresses hepatic LPA gene expression [4]. Oral estrogen-containing hormone replacement therapy can lower Lp(a) by 20 to 25%, though this is not an approved indication and must be weighed against other HRT risks and benefits [19]. Premenopausal women with borderline Lp(a) should be aware that their levels may rise during the menopausal transition.

Patients of African Descent

Individuals of African descent have higher median Lp(a) levels than individuals of European descent, with median values roughly two to three times higher [2]. The relationship between Lp(a) and cardiovascular risk in this population is confirmed but whether the same absolute thresholds (50 mg/dL, 125 nmol/L) apply equally is still debated. The ARIC study (N=9,851 Black participants) found continuous risk association without a clear threshold effect [20].

Practical Ordering Guide

Ordering Lp(a) is simple. Use CPT code 83695 for the immunoassay. Most major commercial laboratories (Quest, Labcorp, and hospital reference labs) offer the test. Results typically return within 1 to 3 business days.

Insurance coverage is inconsistent. Medicare and most commercial insurers cover Lp(a) when ordered for patients with personal or family history of premature ASCVD, familial hypercholesterolemia, or unexplained recurrent cardiovascular events. For screening in otherwise low-risk patients, out-of-pocket cost ranges from $20 to $50 at direct-access labs.

Request results in nmol/L when possible. If your lab only reports mg/dL, avoid using a fixed conversion factor because the relationship between mass and molar units depends on apo(a) isoform size. A rough approximation multiplies mg/dL by 2.0 to 2.5 to estimate nmol/L, but this introduces meaningful imprecision [7].

Repeat testing is generally unnecessary. If Lp(a) is normal on first measurement, it will almost certainly remain normal. If elevated, confirm with one repeat test and then focus clinical effort on total risk reduction rather than serial Lp(a) monitoring. Recheck only if the patient develops nephrotic syndrome, severe hypothyroidism, or begins a medication known to affect levels (such as PCSK9 inhibitors, niacin, or hormone therapy).

Communicating Results to Patients

Telling someone their Lp(a) is high requires careful framing. Patients need to understand three things: this is genetic, it cannot be dieted away, and there are still meaningful actions they can take.

The 2024 EAS consensus recommends presenting Lp(a) in the context of "lifetime risk" rather than short-term event probability [4]. A 40-year-old with Lp(a) of 200 nmol/L and no other risk factors may have a modest 10-year ASCVD risk by pooled cohort equation, but their cumulative exposure over 40 more years is substantial.

Dr. Sotirios Tsimikas, professor of medicine at UC San Diego and a leading Lp(a) researcher, has described the clinical conversation this way: "We tell patients their Lp(a) is like a speed limit on a highway. You can't change the posted limit, but you can make sure you're driving the safest car possible by controlling blood pressure, LDL-C, glucose, weight, and not smoking" [21].

Cascade screening of first-degree relatives is appropriate when Lp(a) exceeds 125 nmol/L. Since the trait is autosomal codominant, approximately 50% of first-degree relatives will also be affected.

The 2019 NLA scientific statement recommends Lp(a) measurement in children and adolescents with a family history of premature ASCVD or elevated Lp(a), particularly to inform early lifestyle counseling and long-term cardiovascular planning [22].